CStone Pharmaceuticals' (HKG:2616) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The CStone Pharmaceuticals (HKG:2616) share price has softened a substantial 26% over the previous 30 days, handing back much of the gains the stock has made lately. Regardless, last month's decline is barely a blip on the stock's price chart as it has gained a monstrous 328% in the last year.

Although its price has dipped substantially, CStone Pharmaceuticals may still be sending very bearish signals at the moment with a price-to-sales (or "P/S") ratio of 49.3x, since almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios under 17.1x and even P/S lower than 7x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

See our latest analysis for CStone Pharmaceuticals

How CStone Pharmaceuticals Has Been Performing

CStone Pharmaceuticals could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. It might be that many expect the dour revenue performance to recover substantially, which has kept the P/S from collapsing. However, if this isn't the case, investors might get caught out paying too much for the stock.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on CStone Pharmaceuticals.

Do Revenue Forecasts Match The High P/S Ratio?

CStone Pharmaceuticals' P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.

Retrospectively, the last year delivered a frustrating 56% decrease to the company's top line. The last three years don't look nice either as the company has shrunk revenue by 52% in aggregate. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.

Looking ahead now, revenue is anticipated to climb by 181% during the coming year according to the three analysts following the company. That's shaping up to be materially lower than the 554% growth forecast for the broader industry.

With this in consideration, we believe it doesn't make sense that CStone Pharmaceuticals' P/S is outpacing its industry peers. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.

What We Can Learn From CStone Pharmaceuticals' P/S?

A significant share price dive has done very little to deflate CStone Pharmaceuticals' very lofty P/S. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

It comes as a surprise to see CStone Pharmaceuticals trade at such a high P/S given the revenue forecasts look less than stellar. When we see a weak revenue outlook, we suspect the share price faces a much greater risk of declining, bringing back down the P/S figures. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable.

Before you settle on your opinion, we've discovered 2 warning signs for CStone Pharmaceuticals that you should be aware of.

If these risks are making you reconsider your opinion on CStone Pharmaceuticals, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.